Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

Stopped

Open to: ALL

Age: 18.0 - N/A

Medical Conditions

Kidney Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Hypertrophy, Left Ventricular
Hypertrophy


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


To evaluate the effects of paricalcitol injection on cardiac structure and function over 48 weeks in subjects with Stage 5 Chronic Kidney Disease (CKD) receiving hemodialysis who have left ventricular hypertrophy (LVH).

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jan 2009 May 2009

Publications

"Thadhani R. Targeted ablation of the vitamin D 1alpha-hydroxylase gene: getting to the heart of the matter. Kidney Int. 2008 Jul;74(2):141-3. doi: 10.1038/ki.2008.219."; "18591942"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Paricalcitol Injection 4 mcg/mL intravenously three times a week during dialysis

Intervention Arm Group : Paricalcitol Injection 4 mcg/mL;

Intervention Type : DRUG
Intervention Description : Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis

Intervention Arm Group : Placebo Injection 4 mcg/mL;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Hammersmith Hospital
    London
    W12 0NN
  • University Hospitals Coventry and Warwickshire NHS Trust - University Hospital (UHCW)
    Coventry
    CV2 2DX
  • Salford Royal NHS Foundation Trust - Dept. of Nephrology
    Salford
    M6 8HD


The study is sponsored by Abbott and is in collaboration with Massachusetts General Hospital; Harvard University.





We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT00616902
Last updated 18 January 2012

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.